Pradeep K. Nair, MD, FACC, FSCAI; Bret N. Wiechmann, MD, FSIR, FAHA; S. Jay Mathews, MD, MS, FACC, FSCAI; Fadi Saab, MD, FACC, FSCAI; Craig M. Walker, MD, FACC, FACP, FSCAI, FCCP
This live case from AMP 2024 features an exciting innovation in peripheral disease management: the powerful combination of Makoto IVUS and the Aperta NSE PTA Scoring Balloon.
This live case from AMP 2024 features an exciting innovation in peripheral disease management: the powerful combination of Makoto IVUS and the Aperta NSE PTA Scoring Balloon.
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI; Zola N'Dandu, MD; Sonya Noor, MD; Robert A. Lookstein, MD
Watch this live case symposium and expert panel discussion on drug elution and vessel prep treatment algorithms featuring Drs. Eric Secemsky, Zola N'Dandu, Sonya Noor, and Robert Lookstein that was recorded at AMP 2024.
Watch this live case symposium and expert panel discussion on drug elution and vessel prep treatment algorithms featuring Drs. Eric Secemsky, Zola N'Dandu, Sonya Noor, and Robert Lookstein that was recorded at AMP 2024.
In this complex case, endovascular intervention was performed on a patient with CFA and SFA disease presenting with ischemic rest pain. IVUS was used to identify and quantify the lesions.
In this complex case, endovascular intervention was performed on a patient with CFA and SFA disease presenting with ischemic rest pain. IVUS was used to identify and quantify the lesions.
In this Live CLI case, endovascular intervention is performed via the brachial and pedal arteries in a patient with a complex CFA and SFA CTO with limited access options. Multiple crossing and treatment modalities are utilized in this case to...
In this Live CLI case, endovascular intervention is performed via the brachial and pedal arteries in a patient with a complex CFA and SFA CTO with limited access options. Multiple crossing and treatment modalities are utilized in this case to...
This complex CLI case highlights multilevel treatment in a patient with initial claudication that progressed to rest pain and is successfully treated from an antegrade femoral approach with multiple treatment modalities utilized. Featuring...
This complex CLI case highlights multilevel treatment in a patient with initial claudication that progressed to rest pain and is successfully treated from an antegrade femoral approach with multiple treatment modalities utilized. Featuring...
During this complex CLI procedure, endovascular intervention was performed utilizing 3 access points and multiple modalities for treatment of above and below the knee disease in a patient with pain and ulcers of the foot. Featuring operator...
During this complex CLI procedure, endovascular intervention was performed utilizing 3 access points and multiple modalities for treatment of above and below the knee disease in a patient with pain and ulcers of the foot. Featuring operator...
The announcement follows successful results in a multi-site clinical study with U.S. Renal Care, one of the nation's largest dialysis providers, showing early clinical validation of VxWave in routine dialysis clinic workflows.
The announcement follows successful results in a multi-site clinical study with U.S. Renal Care, one of the nation's largest dialysis providers, showing early clinical validation of VxWave in routine dialysis clinic workflows.
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
